To tackle the ongoing high burden of hepatitis C virus (HCV) infections among people who inject drugs (PWID), WHO has set a specific incidence target among PWID of no more than two new infections per ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, researchers have identified a vulnerability that opens ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

We expect investors to focus on the sales performance of ADMA Biologics’ ADMA portfolio of marketed products and other ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. "Gilead delivered another exceptionally ...

Long COVID, a debilitating condition following SARS-CoV-2 infection, continues to disable tens of millions of people globally ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

A recent study from Temple University finds a majority of Pennsylvania college students consider themselves educated about ...

Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports ...

but one hepatitis C study, which recruited homeless individuals from shelters, special projects and medical centres in Oxford, found 26.5% of individuals positive using oral fluid testing.25 Our ...

However, with the widespread use of PD-1 inhibitors, there are increasing reports of immune-related adverse events (irAEs) in clinical practice, with immune-related hepatitis (IRH ... revealing the ...